Ultragenyx
Entity.
- Evidence
- 24 documents · 16 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 11 Aug 2026, last seen 8 Oct 2026
- Measured
- 46% of mentions say something specific about it; the rest only name it
- As of
- 9 Oct 2026
Where this comes from
- AllSci News · 2026-10-08 · Ultragenyx to sell FDA priority review voucher for USD 210 million (opens the source in a new tab)
- Endpoints News · 2026-10-07 · Ultragenyx sells PRV for $210M and still has another to monetize (opens the source in a new tab)
- MarketBeat News Feed · 2026-09-26 · Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts (opens the source in a new tab)
- BioPharma Dive · 2026-09-19 · Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug (opens the source in a new tab)
- Endpoints News · 2026-09-19 · FDA approves Ultragenyx's gene therapy for Sanfilippo syndrome type A (opens the source in a new tab)
- Fierce Pharma · 2026-09-18 · FDA approves Ultragenyx’s gene therapy Fayuvi for rare neurodegenerative disorder (opens the source in a new tab)
- MarketBeat News Feed · 2026-09-18 · Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock (opens the source in a new tab)
- MarketBeat News Feed · 2026-09-16 · Ultragenyx Pharmaceutical (NASDAQ:RARE) CAO Theodore Alan Huizenga Sells 1,283 Shares of Stock (opens the source in a new tab)
- STAT News · 2026-09-04 · STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more (opens the source in a new tab)
- STAT News · 2026-09-03 · STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial (opens the source in a new tab)
- SEC EDGAR · 2026-08-11 · 8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer) [Other Events] (opens the source in a new tab)